Biotheryx, Inc.

Biotheryx, Inc. is a leading clinical-stage biopharmaceutical company dedicated to discovering and developing innovative protein degradation therapies. Focused on creating first-in-class protein degraders, including bifunctional degraders and molecular glues, Biotheryx is committed to addressing validated targets in cancer and inflammatory diseases. The company’s proprietary PRODEGY platform builds upon extensive expertise in Cereblon binding, leveraging the knowledge of team members who previously developed the IMiDs, the first FDA-approved modulators of Cereblon. The primary address of Biotheryx is 10201 Wateridge Circle, Suite 100, San Diego, California 92121, US.

Biotheryx’s clinical program, BTX-9341, a bifunctional degrader of CDK4 and CDK6, has entered a Phase 1 clinical trial, marking a significant step forward in the fight against cancer. Additionally, Biotheryx is advancing BTX-10908, a first-in-class degrader of SOS1 for pan-KRAS mutant cancers, and PDE4 degraders for inflammatory diseases. These cutting-edge programs demonstrate Biotheryx's dedication to pioneering new treatments and improving patient outcomes. Biotheryx is poised to make substantial contributions to the biotechnology landscape with its innovative approach to targeted protein degradation.

Located in San Diego, California, Biotheryx, Inc. is at the forefront of biotechnology research. The company’s commitment to innovation and patient care drives its ongoing efforts to develop transformative therapies. We invite the management team at Biotheryx to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.